NCT01896479View on ClinicalTrials.gov

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

247

Participants

Timeline

Start Date

February 25, 2015

Primary Completion Date

July 15, 2020

Study Completion Date

January 31, 2035

Conditions

Medullary Thyroid Cancer

Interventions

DRUG

Cabozantinib (XL184) 140 mg

DRUG

Cabozantinib (XL184) 60 mg

DRUG

Placebo tablet

DRUG

Placebo capsule

Trial Locations (49)

1000

Zagreb

1088

Budapest

2065

St Leonards

3050

Parkville

4006

Herston

4032

Debrecen

5037

Kurralta Park

10000

Zagreb

10153

Torino

10825

Bucharest

11863

Bucharest

13100

Safed

20133

Milan

21079

Dijon

28034

Madrid

28046

Madrid

31000

Osijek

33076

Bordeaux

35138

Padua

49100

Petah Tikva

49933

Angers

53100

Siena

56124

Pisa

67065

Strasbourg

69373

Lyon

75013

Paris

75185

Uppsala

91120

Jerusalem

94805

Villejuif

95124

Catania

110744

Seoul

150040

Yaroslavl

197089

Saint Petersburg

249036

Obninsk

300723

Timișoara

400058

Cluj-Napoca

410769

Goyang

630068

Novosibirsk

JIH 5N4

Québec

M5G 2M9

Toronto

00161

Roma

1066 CX

Amsterdam

2333 ZA

Leiden

9713 GZ

Groningen

60-355

Poznan

44-100

Gliwice

135-710

Seoul

08035

Barcelona

SE-22185

Lund

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY